Pathos AI raises $237M to scale AI-driven cancer drug development

What's Happening

• Pathos AI raised $237 million in Series E funding at a $3 billion valuation, the company announced.
• Pharmaceutical giant Bristol Myers Squibb led the round, joining returning backers AstraZeneca, NEA, and General Atlantic.
• The startup will use the capital to finance its drug development efforts, prioritizing an antibody-drug conjugate cancer therapy called JSKN016.

Why It Matters

The pharmaceutical industry struggles with high failure rates in clinical trials. Pathos AI uses massive datasets to identify viable drug candidates before testing begins, reducing wasted capital and accelerating the timeline for bringing oncology treatments to market.